These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 21840642)

  • 1. External validation of postoperative nomograms for prediction of all-cause mortality, cancer-specific mortality, and recurrence in patients with urothelial carcinoma of the bladder.
    Nuhn P; May M; Sun M; Fritsche HM; Brookman-May S; Buchner A; Bolenz C; Moritz R; Herrmann E; Burger M; Tilki D; Trojan L; Perrotte P; Haferkamp A; Hohenfellner M; Wieland WF; Müller SC; Karakiewicz PI; Bastian PJ
    Eur Urol; 2012 Jan; 61(1):58-64. PubMed ID: 21840642
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Concomitant carcinoma in situ in cystectomy specimens is not associated with clinical outcomes after surgery.
    Nuhn P; Bastian PJ; Novara G; Svatek RS; Karakiewicz PI; Skinner E; Fradet Y; Izawa JI; Kassouf W; Montorsi F; Müller SC; Fritsche HM; Sonpavde G; Tilki D; Isbarn H; Ficarra V; Dinney CP; Shariat SF
    Urol Int; 2011; 87(1):42-8. PubMed ID: 21659717
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Predicting individual outcomes after radical cystectomy: an external validation of current nomograms.
    Zaak D; Burger M; Otto W; Bastian PJ; Denzinger S; Stief CG; Buchner H; Hartmann A; Wieland WF; Shariat SF; Fritsche HM
    BJU Int; 2010 Aug; 106(3):342-8. PubMed ID: 20002664
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nomogram for predicting disease recurrence after radical cystectomy for transitional cell carcinoma of the bladder.
    Karakiewicz PI; Shariat SF; Palapattu GS; Gilad AE; Lotan Y; Rogers CG; Vazina A; Gupta A; Bastian PJ; Perrotte P; Sagalowsky AI; Schoenberg M; Lerner SP
    J Urol; 2006 Oct; 176(4 Pt 1):1354-61; discussion 1361-2. PubMed ID: 16952631
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Postoperative nomogram for invasive bladder cancer: does it really work? A multicenter cohort study.
    Bassi PF; Bongiovanni L; Racioppi M; Volpe A; D'Agostino D; Gardi M; ;
    Urol Oncol; 2011; 29(6):698-702. PubMed ID: 19959381
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lymph node dissection technique is more important than lymph node count in identifying nodal metastases in radical cystectomy patients: a comparative mapping study.
    Dorin RP; Daneshmand S; Eisenberg MS; Chandrasoma S; Cai J; Miranda G; Nichols PW; Skinner DG; Skinner EC
    Eur Urol; 2011 Nov; 60(5):946-52. PubMed ID: 21802833
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Risk factors and outcomes of urethral recurrence following radical cystectomy.
    Boorjian SA; Kim SP; Weight CJ; Cheville JC; Thapa P; Frank I
    Eur Urol; 2011 Dec; 60(6):1266-72. PubMed ID: 21871713
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nomograms provide improved accuracy for predicting survival after radical cystectomy.
    Shariat SF; Karakiewicz PI; Palapattu GS; Amiel GE; Lotan Y; Rogers CG; Vazina A; Bastian PJ; Gupta A; Sagalowsky AI; Schoenberg M; Lerner SP
    Clin Cancer Res; 2006 Nov; 12(22):6663-76. PubMed ID: 17121885
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neurofuzzy modeling to determine recurrence risk following radical cystectomy for nonmetastatic urothelial carcinoma of the bladder.
    Catto JW; Abbod MF; Linkens DA; Larré S; Rosario DJ; Hamdy FC
    Clin Cancer Res; 2009 May; 15(9):3150-5. PubMed ID: 19336522
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pathologic downstaging is a surrogate marker for efficacy and increased survival following neoadjuvant chemotherapy and radical cystectomy for muscle-invasive urothelial bladder cancer.
    Rosenblatt R; Sherif A; Rintala E; Wahlqvist R; Ullén A; Nilsson S; Malmström PU;
    Eur Urol; 2012 Jun; 61(6):1229-38. PubMed ID: 22189383
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Multiple biomarkers improve prediction of bladder cancer recurrence and mortality in patients undergoing cystectomy.
    Shariat SF; Karakiewicz PI; Ashfaq R; Lerner SP; Palapattu GS; Cote RJ; Sagalowsky AI; Lotan Y
    Cancer; 2008 Jan; 112(2):315-25. PubMed ID: 18008359
    [TBL] [Abstract][Full Text] [Related]  

  • 12. International validation of the prognostic value of lymphovascular invasion in patients treated with radical cystectomy.
    Shariat SF; Svatek RS; Tilki D; Skinner E; Karakiewicz PI; Capitanio U; Bastian PJ; Volkmer BG; Kassouf W; Novara G; Fritsche HM; Izawa JI; Ficarra V; Lerner SP; Sagalowsky AI; Schoenberg MP; Kamat AM; Dinney CP; Lotan Y; Marberger MJ; Fradet Y
    BJU Int; 2010 May; 105(10):1402-12. PubMed ID: 20132195
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Multi-institutional validation of the predictive value of Ki-67 labeling index in patients with urinary bladder cancer.
    Margulis V; Lotan Y; Karakiewicz PI; Fradet Y; Ashfaq R; Capitanio U; Montorsi F; Bastian PJ; Nielsen ME; Müller SC; Rigaud J; Heukamp LC; Netto G; Lerner SP; Sagalowsky AI; Shariat SF
    J Natl Cancer Inst; 2009 Jan; 101(2):114-9. PubMed ID: 19141773
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cancer-specific and other-cause mortality after radical prostatectomy versus observation in patients with prostate cancer: competing-risks analysis of a large North American population-based cohort.
    Abdollah F; Sun M; Schmitges J; Tian Z; Jeldres C; Briganti A; Shariat SF; Perrotte P; Montorsi F; Karakiewicz PI
    Eur Urol; 2011 Nov; 60(5):920-30. PubMed ID: 21741762
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Development of a new outcome prediction model in carcinoma invading the bladder based on preoperative serum C-reactive protein and standard pathological risk factors: the TNR-C score.
    Gakis G; Todenhöfer T; Renninger M; Schilling D; Sievert KD; Schwentner C; Stenzl A
    BJU Int; 2011 Dec; 108(11):1800-5. PubMed ID: 21507193
    [TBL] [Abstract][Full Text] [Related]  

  • 16. p53 predictive value for pT1-2 N0 disease at radical cystectomy.
    Shariat SF; Lotan Y; Karakiewicz PI; Ashfaq R; Isbarn H; Fradet Y; Bastian PJ; Nielsen ME; Capitanio U; Jeldres C; Montorsi F; Müller SC; Karam JA; Heukamp LC; Netto G; Lerner SP; Sagalowsky AI; Cote RJ
    J Urol; 2009 Sep; 182(3):907-13. PubMed ID: 19616250
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A population based assessment of perioperative mortality after cystectomy for bladder cancer.
    Isbarn H; Jeldres C; Zini L; Perrotte P; Baillargeon-Gagne S; Capitanio U; Shariat SF; Arjane P; Saad F; McCormack M; Valiquette L; Peloquin F; Duclos A; Montorsi F; Graefen M; Karakiewicz PI
    J Urol; 2009 Jul; 182(1):70-7. PubMed ID: 19447427
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Associations between comorbidity, and overall survival and bladder cancer specific survival after radical cystectomy: results from the Alberta Urology Institute Radical Cystectomy database.
    Fairey AS; Jacobsen NE; Chetner MP; Mador DR; Metcalfe JB; Moore RB; Rourke KF; Todd GT; Venner PM; Voaklander DC; Estey EP
    J Urol; 2009 Jul; 182(1):85-92; discussion 93. PubMed ID: 19447413
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic risk stratification of pathological stage T2N0 bladder cancer after radical cystectomy.
    Sonpavde G; Khan MM; Svatek RS; Lee R; Novara G; Tilki D; Lerner SP; Amiel GE; Skinner E; Karakiewicz PI; Bastian PJ; Kassouf W; Fritsche HM; Izawa JI; Ficarra V; Dinney CP; Lotan Y; Fradet Y; Shariat SF
    BJU Int; 2011 Sep; 108(5):687-92. PubMed ID: 21087453
    [TBL] [Abstract][Full Text] [Related]  

  • 20. External beam radiation therapy followed by interstitial radiotherapy with iridium-192 for solitary bladder tumours: results of 111 treated patients.
    van Onna IE; Oddens JR; Kok ET; van Moorselaar RJ; Bosch JL; Battermann JJ
    Eur Urol; 2009 Jul; 56(1):113-21. PubMed ID: 18722048
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.